Good afternoon, welcome to Moderna's COVID-19 vaccine update. At this time, all participants are in listen only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded. At this time, I'd like to turn the call over to Lavina Talukdar, Head of Investor Relations at Moderna. Please proceed.
Thank you, operator. Hello everyone, and thank you for joining us on today's call to discuss new data points, including clinical data and analysis from our one-year follow-up of our phase III COVE study. You can access the press release issued this afternoon, as well as the slides that we will be reviewing by going to the investor section of our website. On today's call are Stéphane Bancel, our Chief Executive Officer, Stephen Hoge, our President, Paul Burton, our Chief Medical Officer, and Jacqueline Miller, Senior Vice President, Therapeutic Head of Infectious Diseases at Moderna. Before we begin, please note that this conference call will include forward-looking statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
Please see slide two of the accompanying presentation in our Securities and Exchange Commission filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. On slide three, please see the important indication and safety information for our COVID-19 vaccine, which has been authorized for emergency use in the U.S. and in many other countries around the world. Stephen will take us through the slide presentation, and will be joined by Stéphane, Paul, and Jackie during the Q&A session. With that, I will hand it over to Stephen Hoge.
Thank you, Lavina. Good afternoon and good evening, everyone. Thanks for spending some time with us. I'd like to cover a few topics today that were covered in a press release just sent out a half hour ago. First, we'd like to review some of the recent vaccine effectiveness data from the real world about the Moderna vaccine and against the Delta variant. Second, I'd like to provide an update on some recent data from our phase III COVE study, looking at breakthrough infections that might inform the use of booster dose, as well as immunogenicity data on a vaccine booster, and then lastly, summarize our current thinking about a booster dose. First, summarizing some of the real world evidence. Moderna's COVID-19 vaccine remained effective in the face of that Delta surge through a median of approximately three and a half months post completed vaccination.
In fact, as highlighted in the red at the bottom, you can see vaccine efficacy for Moderna's mRNA-1273. It was 95%, with a 95% confidence interval of 92%-97%. That was the highest vaccine efficacy across the different vaccines. That real-world effectiveness is very encouraging and gives us confidence that as of today, the mRNA-1273 vaccine is really providing strong protection against all variants of concern, including Delta. The big question we're all wrestling with right now scientifically is what does this look like in the future? Not today, but towards the end of this year, as many people across the world will start approaching their first anniversary of vaccination. Where will we be at about one year? The best way we can look at that is through our phase III study.
That's because the folks who participated in our phase III study are among the earliest recipients of mRNA-1273. In fact, most of them were vaccinated over a year ago when they received their first dose in August and September of 2020. We're able to look at the effectiveness of the vaccine because we can compare those that received vaccine and vaccination, as you can see are highlighted in blue, are in the early 1273 group in August, September and October, against those who were originally randomized to placebo, and therefore participated in the blinded study, but at Emergency Use Authorization and crossover, were then offered the vaccine and overwhelmingly accepted it, and were vaccinated in January and February of this year. That creates a window.
Two different cohorts in the same study that we're following in our phase III, many of whom have been vaccinated on median of about a year ago, and a second half who've been vaccinated a median of about seven months ago, as we entered the period of time when Delta surged in the U.S. As we started to look at the increase in cases of Delta in our study, as you'll note at the bottom, the number of COVID-19 breakthrough cases among vaccine recipients surged quite significantly from single digits to low double digits prior to June 2021, to 81 and 169 cases in July and August respectively.
That large Delta surge was captured as vaccine breakthroughs between those two groups, and by comparing those groups and the relative risk of being in the 11-13 month cohort, approximately vaccinated one year ago, and those that are six to eight months since their first vaccination during that surge, we can develop a view of what the impact of waning immunity between one year and approximately six to seven months would be. That data was summarized in the preprint that we posted today. Briefly, if you look at those two cohorts on the next slide, you'll see that at baseline heading into that risk window, they were largely the same.
First looking at the mRNA-1273E cohort on the left, you'll note that there were 14,700 participants, and in the original placebo group called mRNA-1273T here, there are 11,400 participants. The difference, approximately 3,000 participants, is made up of two main groups, those that had come down with COVID-19 prior to vaccination in the placebo group, of which there was nearly 1,000 cases. Secondarily, those that decided to leave the study at the end of last year, to pursue vaccination through another means, once being notified that they were on placebo. If you compare the groups across the different demographic and risk factors, you'll note that they are still substantially the same. In fact, the age between the groups is similar at 51, 52. First highlighted blue row.
What you'll note is there are 162 cases in our original vaccination group of about a year ago, and that equates to a rate of about 77 per thousand person years. That compares with about 88 cases in the more recent vaccination group of about the last six months, at a rate of 49 per thousand person years. That actually leads to a significant relative reduction in risk. In fact, if you look at the difference and the reduction in risk observed with being less than 6 months or approximately six months from your last dose of vaccine, there's a 36% reduction in risk and the 95% confidence intervals, as you can see, are significant, with a range of 17%-51%.
That is also true if you look at the 18-65 population underneath, and there's a numerical trend in the same direction, although numbers substantially lower for the 65 and older population. Now, as we go down, you'll also note that the numbers become smaller, but the trends generally hold. First looking at severe disease, you'll see that there are 13 cases of severe disease in the folks vaccinated last year, comparing with six cases of severe disease in those more recently vaccinated. That is approximately a twofold increase or a 46% reduction in risk. Perhaps a numerical trend towards slightly higher numbers as you move to the 65+ population with six cases of severe disease in the older vaccination group and only two cases in the more recent group.
On the next slide, I'd like to provide a little bit more of an overview of the severity that we're seeing across this group, for context. Again, all present in the manuscript. If you look at overall per protocol COVID-19 cases, there were 250, and as you'll note, there was approximately a 2: 1 ratio between those that were early versus more recently vaccinated. In terms of severe cases I just covered a moment ago, 13 and six, and again, directionally approximately a 2: 1 ratio. There were three instances of hospitalization in those, and all three were in the cohort that was vaccinated over a year ago. There were two tragic cases of death from COVID-19, both present in those vaccinated in the early cohort with a median follow-up of 13 months.
Overall, severe disease was present in this population, and it accounted in total for about 7.6% of the cases. All severe diseases, when present, had over five symptoms for COVID-19 with a range of 5-13 symptoms. The majority of cases did meet the protocol criteria based on low O2 sat, with a range of 88%-93%, so hypoxia. If you look among the severe cases, there was a trend towards greater severity in the earlier vaccination cohort. As you'll note in the pre-print, severe cases were seen across all age groups, including in participants who do not have any known risk factors for severe COVID-19. How do we estimate what that impact would look like? What does this quantification from the phase III study suggest to us?
First, the phase III study does give us a direct approximation or estimate of the impact of waning immunity on protection against COVID-19 and allows us to estimate what the increased risk of COVID-19 breakthrough will be as we look forward into the future, which is the question that we're all wrestling with right now. If we estimate the impact of being greater than seven months from your last dose in the U.S., which is a comparison of those two groups, and we extrapolate again within the U.S. where the study was conducted across the 66 million adults in the U.S. who received 1273, you'd expect approximately 28 cases per 1,000 person years of exposure. That would be about 1.9 million cases per year of exposure.
If you divide that by 12 months, that's an incremental 150,000 cases of COVID-19 per month that are related to what we would characterize as waning immunity. Again, all of the participants in both arms of the study were exposed, we believe, to the same risk in this country, having previously randomized geographically across the country. They were all exposed during the time between July 1st and August 27th when the majority of the sequences and cases were Delta variant of concern. What does that mean for us as we look forward? This is only one estimate and one way to look at it, but we do believe that this means as you look towards the fall and winter in the U.S., we would estimate the impact of waning immunity at a minimum to be approximately 600,000 additional cases of COVID-19.
As I covered a moment ago, although the numbers are low, we would expect some of those cases to be severe, and unfortunately, some might result in hospitalization and death. This begins to form the impetus for why we think a booster vaccine is necessary. In the last few slides, I'll try and summarize how we're viewing the booster in the context of this data, and the clinical data that we have on the 50 mcg booster. First, we do believe a third dose booster will reduce the risk of COVID-19 based on the data I just presented. Illustratively here, we're showing a view of what immunity might look like, and again, strength of immunity in the study as we conducted it. Is this a surrogate for neutralizing titers? Perhaps, it is not actually neutralizing titers.
Nonetheless, you get the idea of what we believe we've now measured in the phase III study, which is we have a group of participants who were vaccinated approximately a year ago, and a second group who were vaccinated at the early part of 2021, approximately eight months ago. Both, we believe, would achieve similar levels of immunity given their similar profiles, and we would've seen some waning in that immunity over time. And what we're able to do today is to take a snapshot in July and August of this year, as denoted by the number one here, and say, well, what's the impact of that difference in the level of immunity that was achieved as a function of time, as a function of waning?
What we now know is that there is a significant difference between those that were eight or 13 months from their last dose of vaccine. We believe that that's approximately equivalent to 150,000 potential incremental cases of COVID-19 per month in the U.S. as a result of waning immunity. It's not the only breakthrough infections that are happening, but it is the Delta measured by that month. That becomes something we would hope to try and address with a booster vaccine, which would boost that immunity back up, hopefully to levels that are more like where we were immediately following vaccination. On this slide, I'm sharing again some data that had been previously presented at our R&D Day, showing neutralizing titers following the 50 mcg booster that we've filed with regulators for mRNA-1273.
Just quickly to orient you to the data that's on the slide, all of the data here has been done in the clinically validated National Institutes of Health assays, for which we are very grateful for their help. It is the data that covers both our phase III study on the left-hand side in an immune cohort, and our phase II booster study, which was recently completed, filed with the Food and Drug Administration. First is the phase III COVE study. One month post-vaccination, as you can see, the geometric mean titers in that cohort one month after vaccination was approximately 1,000 or 1,081 with a very nice tight 95% confidence interval.
That's the bar that we want to get back to, or perhaps slightly exceed, but get back to that bar to make sure that we address the question of waning immunity, because that is ultimately what we believe fell away.
As you'll note in the phase II portion, we did have pre-boost titers. Again, this was previously presented, but six to eight months after people who have been vaccinated, those titers had waned substantially, down to approximately 126. That responded very well to boosting. As Jackie presented a week ago, a post-boost titer in that same booster study, 50 mcg of 1273 as a dose three, increased titers in all participants up to a level that was significantly higher than the phase III benchmark that we set ourselves. In fact, titers of 1,893. If you just look at the 65+ subcohort within those roughly 300 people, 76 of them were 65+ . You see again, the titers were significantly above the phase III benchmark, even including younger healthy adults in that phase III benchmark, reaching titers of 1,762.
We do believe that a 50 mcg dose not only achieves the objective of getting to the same level of protection that you had prior to waning immunity, but actually significantly exceeds that by a factor of 1.7. On the next slide, if I bring us back to that illustrative picture, what we think that means is that a booster dose given today will increase the strength of that immunity, not just to levels that you had to the left of the chart, but to levels that are significantly above it, maybe perhaps 1.7-fold above it. We know that a 50 mcg booster will be able to do that. That should counteract at a minimum the waning immunity, and we believe this will reduce COVID-19 cases to an even greater extent than is measured by the waning immunity as noted by number one. How much greater? We can't say.
We believe there will be some benefit, but it is not currently possible to give a specific answer on that number, but we believe it'll be better. That's not the only advantage of boosting. On the next slide, we also believe that a third dose of mRNA-1273 has a chance of significantly extending immunity throughout much of next year as we seek to end the pandemic. It has been well just demonstrated, both in our prior work, including with the cytomegalovirus vaccine, mRNA-1647, as well as in other vaccines, that a delayed booster does help refine the immune response and actually can lead to a different curve for waning immunity, so longer, more durable protection. We do not currently have any data on what that would look like.
We're going to be collecting it through our phase III study, including those that just recently received their 50 mcg booster in phase II, but also phase III by continuing to study the value of any boosters. We hope over time we'll be able to add evidence that there's more durable immunity following that third dose. Overall, while we think that there is a clear benefit to the vaccine right now, and continued evidence of waning immunity as we've quantified as of a moment ago, we do think that there are additional benefits that can emerge with a second dose, both by increasing titers significantly above the level seen in phase III and by perhaps extending the durability of immunity.
With that, I'd like to turn it over to the operator and invite any questions from any of you about the data we've covered today or our approach review on boosters.
Certainly. Ladies and gentlemen, if you have a question at this time, please press star then one on your touchtone telephone. If your question has been answered and you'd like to remove yourself from the queue, please press the pound key. Our first question comes from the line of Salveen Richter from Goldman Sachs. Your question please.
Great. Good afternoon. Thank you for taking our question. This is Elizabeth on for Salveen. In light of your data, the real-world data that's been emerging over the past few months now, and ahead of the FDA meeting this Friday, what do you view as the key outstanding debates around the timing of booster administration, so how long after the primary series the boost is given, and around the use outside of immunocompromised individuals?
Thank you for the question. It's a great one. It's one that really, I'd say, is only partially directed to Moderna, because at the end of the day, the deployment of interventions like a booster in the pandemic really should be decisions made by public health officials, including the Centers for Disease Control and Prevention and FDA. That said, the questions that we have or the position that we have as a company is we do think there is building evidence already, for instance, from the phase III study I just presented here, that there is a benefit to be had from boosting. Not just boosting those that are immunocompromised. We already have a third dose for immunocompromised population to help them get to the highest levels of immunity, get to the same levels of immunity we would hope as we saw with healthy people.
Instead, actually adding a 50 mcg boost to help get everybody else who may be six months or later from their vaccine booster back to the level of immunity they had immediately following vaccination. We think that's prudent this year because there is still so much circulation of the SARS-CoV-2 virus, particularly the Delta variant that's happening right now, the pandemic is not over, that we are all going to be exposed to it repeatedly, and we think the risk of waning immunity is particularly high, the risk of that breakthrough. We happen to think that the time for doing that is too early rather than too late. You would rather not be too close on this thing. From our perspective, the data we have right now shows an obvious potential benefit at about six months after your primary series. Six, seven months, give or take.
Our filings and requests with regulators have been to consider amending the authorizations to allow a 50 mcg dose three approximately six months after completing your primary series. We think the data today supports that. The decision of whether or not that actually happens, and then if it is recommended for broad use, is not one for Moderna to make. That really rests with public health officials. We're doing our best to make sure they have the data and the tools in hand if they choose to deploy it in that way.
Great. Thank you so much.
Thank you, Elizabeth.
Thank you. Our next question comes from the line of Matthew Harrison from Morgan Stanley. Your question, please.
Great. Good afternoon. Thanks for taking the question. Stephen, I'm wondering if you can just talk more broadly about, I guess, risk benefit. I think when I read The Lancet editorial, I think there was a focus also on risk of a third dose. Maybe what data have you collected more broadly around safety and reactogenicity from a third dose, and how do you think about risk benefit in that context?
Right. Well, I'll maybe take a first crack at the clinical development data. If I miss anything, I'm sure Jackie will fill in, but then I'll ask Paul to chime in because there's just so much more data that's emerged from the real world on safety, and that's probably the best place to answer the question. First on our clinical trials, we have continued to see a safety and tolerability profile of a third-dose booster that is consistent with the second dose of our vaccine, which has generally been very well tolerated. We have now quite a lot of experience from our clinical trials on that third dose. As you all know and we all will recognize, fortunately, these vaccines have been really well tolerated in mRNA vaccines generally.
Therefore, the adverse events that we're now talking about are exceedingly rare, you count them per million doses delivered, and not something we will ever really be able to see effectively in clinical studies. That's where we have to defer to public health officials, and I might invite Paul to come in and sort of summarize our perspective on the recent data there.
Yeah, absolutely. Thank you. I think there's a couple of important studies to think about. One is, we know the data published by [Victoria Horn] recently in New England Journal, where they actually randomized people, immunocompromised individuals having undergone organ transplantation to that third dose and are able to carefully assess them. We see there a robust safety profile consistent, as Stephen says, with the larger populations that we've studied. That's, I think, very comforting, very reassuring.
Last week as well, we saw published in JAMA by Klein and colleagues, a very nice analysis, 6 million people, 11 million doses, looking using the Vaccine Safety Datalink. This is a network here run by the CDC to be able to look at cases and carefully adjudicate them and look at them. 23 different safety endpoints were identified. Pre-specified criteria for statistical significance were defined.
Not one of those characteristics was met across all of those different 23 safety endpoints. The conclusion I think we have based on the available data is that this is a very safe and effective vaccine. With the available data we have in those other settings that Stephen mentioned, I think we would expect the same to be seen in the booster setting as well.
Thank you, Paul.
You heard that?
Yeah.
Our next question comes from the line of Michael Yee from Jefferies. Your question, please. Michael Yee, you might have your phone on mute. We're still not hearing you. Should we move on to our next questioner?
Yes, please.
Our next question comes from the line of Gena Wang from Barclays. Your question please.
Thank you for taking my questions. I have two questions. First is, given Pfizer seems to show less effective in terms of durability, and they propose six months, do you think a will be longer phase will be required for your booster strategy, i.e., longer than six months? The second question is, do you expect adcom for your boost regimen? We know that we will have one this Friday, do you also expect one for your booster strategy, the regimen? Quickly, when should we expect full approval of the vaccine?
Great. Thank you, Gena Wang, for all three questions. I'll try and take a 1st crack and then invite others to see if I missed anything. I don't think I first cracked all three. First on Pfizer's lower observed effectiveness in the CDC literature and elsewhere. I think we're probably not as guided by the fact that Pfizer has lower effectiveness and therefore is boosting at six months. I think what we're guided by is we have great effectiveness right now in the face of Delta, but we do not want it to wane. If anything, we think the phase III data suggests to us that the first six or eight months are great, but you can't count on that being stable out to one year and beyond. That is really what guides us to sit there and say six months is the right time.
At the end of the day, our goal is to maintain our high effectiveness, which, in the CDC data was 92%, 95%, not wait until we fall to a lower effectiveness like the 77% or 80% that was reported in Pfizer. We would argue that is too late to be boosting, and addressing waning immunity. There are a couple of regulatory questions and I'll of course say that I have to defer on all of these matters to the FDA. As far as whether or not there will be an advisory committee for mRNA-1273, we do not have any guidance on that. We'll, of course, be happy to participate in phase I if the FDA deems that necessary.
It is important to note that we are still proceeding under a slightly different regulatory framework than Pfizer, so we are still operating under an emergency use authorization, although we have completed our Biologics License Application filing, as you noted in your last question. This will be an EUA amendment as opposed to, in Pfizer's case, they're doing a full sBLA. It's quite logical that the FDA may be viewing the obligations of those two differently. Of course, we'd be happy to proceed in any way we are asked. On the question of when to expect authorization, or sorry, full approval, with our BLA. We completed the filing, as everybody knows, in August, towards the end of August.
We are actively working constructively with the FDA as we are with any global regulator to try and answer all of their questions, and make sure they have the information they need. We do not have any guidance or insight into what that timing would be. I suspect, they would say the same, which is that they want to make sure they do all the correct work. I know that our regulatory partners at the FDA are working as hard or harder than we all are, have an incredible amount on their plate right now. I know they are working around the clock, and we're very grateful for all that effort and the engagement that we've seen around the BLA filing. I'm optimistic it will happen quickly. We recognize there are a lot of things happening right now.
Thank you.
Thank you. Our next question comes from the line of Geoff Meacham from Bank of America. Your question please.
Hey, guys. This is Alec on for Geoff. Thanks for taking our questions. First, in your illustrative example, what is the minimum value of the y-axis of the strength of immunity? Trying to get a sense as to your view on the timing of when immunity from the initial vaccination course is effectively depleted. I'm assuming you don't think it's as early as this fall or winter. Can you just remind us, for the supply agreements currently in the U.S., I believe it's somewhere near $500 million, and whether you think this would cover the third dose booster, given the current rate of uptake or if an additional agreement would be needed. Thanks.
Great. Thank you, Alec. I'm going to go to Stéphane in a second on the manufacturing and commercial question. First on the illustrative graph. It is exactly that, illustrative. I think you capture a fair feature of the cartoon that we didn't mean to represent, which is we don't think it will go to zero this fall or winter for sure. Please don't take the cartoon to suggest that. In fact, if you look at the data in the phase III publication that we just posted in the preprint, you see very strong protection still, we believe, even in those that are a year out from vaccination. Please let me be clear. The most valuable thing somebody can do, we can do to end the pandemic is vaccinate the unvaccinated.
Even without a booster, that provides a dramatic benefit, and it looks durable despite the waning. It still looks quite substantial out to a year. The question is there a benefit over and above that protection that you have from that original vaccination, and when did that benefit start to become clear, and what is the magnitude of that? I think that's where we're trying to follow these two cohorts and anticipate that question. Theee months ago, the answer was no, there wasn't a benefit because there weren't a lot of breakthrough cases. You'd sit there and say, look, if people crossed the nine-month threshold, there was no real obvious advantage or not. Two things happened. Delta emerged, and that was a dramatic change in the transmissibility of that virus, and therefore, much more exposures.
The second thing that happened is we played the clock forward another three months, by the time we got to about 12 months on that original vaccination cohort, and you have Delta, you start to see the emergence of a significant difference in the rate of those cases. I believe that if you play that clock forward, you should expect that to become even more significant over time. Now, I don't know how much more significant, but if we imagine that there are going to be additional surges of infections through the fall as people go back to school and as we all move indoors during the fall-winter season, which are respiratory virus seasons, that we're going to see continued transmission, continued infection, and that waning immunity, if not addressed, would become a more significant concern. It will, I would hope, never go to zero level of protection.
Your question of what the origin is, I don't know. It was an illustrative picture, but it's fair to say there's still some protection at that point. We are mainly focused on the difference between the two groups, and that was we're trying to illustrate here. Thank you for that part of the question. Stéphane, do you want to take the question on whether we would need another agreement and supply?
Thanks, Stephen. Alec, I think if you look at where we are, as you know, since around May in the U.S., we've had more vaccines than people wanting to be vaccinated. Thankfully, there's been a little spike in the summer of vaccine use. The 200 million doses to be delivered, 100 million in Q4 and 100 million in Q1, should cover, I would guess, most of the booster needs. That is why I believe the U.S. government has exercised those last options in the contract set up in September 2020 to be able to provide boosters. We should not forget that it's a bit of a complex picture because on the one hand, you have also adolescents and kids that have to be vaccinated as well with prime series.
You repeat that is really hard to monitor and model for us, is how much wastage is happening right now. If you think about it, the U.S. FDA has authorized third dose already for immunocompromised. As you can imagine, if an immunocompromised person goes to a hospital or to a CVS today, I have no idea how many doses in the vial are going to be used. I remind everybody we have currently 10 doses per vial. The wastage amount right now is tough to quantify. Which is why we believe that once we get the BLA, there's going to be a sort of opportunity to be able to provide the private market with the right product to be able to protect every American that needs to be protected. Back to you.
Great. Thank you.
Thank you.
Thank you. Our next question comes from the line of Michael Yee from Jefferies. Your question, please.
Hi, how are you? Can you hear me now?
We can, Michael. How are you?
Very good. I had a two-part question. What I see here is that you're saying that there is reduced efficacy between the two different arms based on the timing of vaccination. I think that's clearly outlined there by 36%. My question is, what do you believe the VE or vaccine efficacy rate is versus a unvaccinated cohort? I think that's what people are trying to struggle with, because even though it might be reduced efficacy, it's still very high efficacy. I think that's what people are trying to struggle with. Question one is, what do you think that is? Maybe the Mayo Clinic addressed that data. Number two is, how do you address the idea of this political discussion around just the idea of everyone just wants to prevent severe and hospitalizations versus actual infections?
I feel like that's actually the issue that's preventing people from being more on board with this. Thank you.
Michael, thank you for both those questions. I'm going to take a stab at the first one and maybe invite Paul to offer his perspective as well from the real-world evidence side. Because this question of what is the relative efficacy of the vaccine right now as it wanes is very hard to answer in clinical trials. In particular, in our phase III study, we do not have that answer because we no longer have a placebo group. So what we can talk about here is a 36% reduction in the risk of having a breakthrough case. 36% reduction, if it's 95% efficacy is very different than if it's 70% efficacy, which is your point. It's very hard for us to know what a reasonable control group would be here. Therefore, there's two s ides to that coin.
One is that there's perhaps even greater benefit to boosting than is quantified by a number like the one we're talking about today. It's very, very difficult, absent real-world evidence, to answer. I might invite, do you want to.
Yeah.
Paul, do you want to take a stab at?
Yeah.
What the real-world evidence might suggest for us in terms of efficacy?
Yeah. Thanks, Stephen. Michael, look, I think another important paper is from Qatar, a paper by Patrick Tang, where they actually are able to look at people unvaccinated, and then with our Moderna vaccine and other mRNA vaccines. What they see when you get into July is in the face of Delta, and they actually genotype cases for Delta, we see vaccine efficacy going down, effectiveness going down to maybe 75%. The Mayo Clinic paper, which you mentioned as well, clearly shows that we're in the maybe 85% realm. In Qatar, exactly as you say, in the face of Delta, we're at maybe 70%-75%. If you take a third cut from that.
You can see that you're getting into the 50%-60%. That really underpins our recommendation for the booster and the timing. We have to be somewhat pragmatic. We know that three months ago, there were only 13,000 people hospitalized. In this country today, there's 91,000. We have to have a pragmatic approach to timing that is going to protect people as much as possible and really protect the healthcare systems here in the U.S. and around the world.
I think it's the idea of trying to get a range of that and not knowing. My second part of the question, which you might want to address, which is, will people just feel like it's preventing severe hospitalizations and still probably preventing infection, so let's just wait?
Michael, this is Jacqueline Miller from the development group, and I guess you're asking a very insightful question, but I want to emphasize that even in real-world evidence, we're never going to be able to get back to the world where we have placebo-controlled trials. Placebo-controlled trial is really the only way to answer the question you're asking. Why is that?
Because unvaccinated people are actually very different than vaccinated people. When you choose to enter a clinical trial, you're randomized. When you choose to be vaccinated in the real world, that often comes with a number of very different behaviors. For example, attitudes towards masking and congregating in large groups inside shopping malls and the like. The point I'm trying to make is that, yes, we still see very high effectiveness in vaccinated versus unvaccinated people, and that should be reassuring to everyone and a good reason to get vaccinated if you haven't already done so. It's not also entirely reassuring in terms of waning persistence and the complex interplay with the emergence of Delta, because we know that individuals who are unvaccinated are already engaging in higher risk behaviors. Amongst the vaccinated populations, we're starting to see a difference.
What component of that is long-term antibody persistence, what component of that is the emergence of Delta, which is a much more highly infectious variant, is really difficult to tease out. Nonetheless, maybe to emphasize your final point, certainly vaccination is the best way to prevent severe disease. We believe that additional vaccinations, especially for people who may have been vaccinated at the beginning of the vaccination program in the U.S., so in particular, the elderly, people with other kinds of high-risk conditions that may not be covered by the current immunocompromised mandate, we believe they would benefit from additional vaccination.
I hope the Advisory Committee on Immunization Practices can understand as well. Yep. Thank you.
Yeah. Just a closing thought on the political question, Michael, because it's a great one. I think we're all trying to figure out, are we okay with COVID-19? Right? From a societal disruption perspective, from a healthcare and morbidity perspective, even from a risk of mortality perspective, and let alone the economic perspective, because those of us with family members that are either at high risk or those of us with kids, have all had to live with the disruption of risk of COVID-19, what it means to our lives. I think there's an aspect of this debate which is playing out in real time, which is COVID-19 all of a sudden acceptable? From a company perspective, from a product development perspective, our answer is no. Our goal with a product is to prevent COVID-19.
That was the original case definition that was in our study, and it was obviously very successful to date with mRNA-1273. We think we need to continue to provide evidence for how the product can do that, how it can prevent symptomatic COVID-19 that meets the criteria in the study, and that's where we think a third dose is necessary. If the public health debate moves off of that and says, "No, now we accept the disruption, economic, social, or healthcare otherwise around it," that's not for us to decide as a company. That's really for society to decide.
It's definitely not clear to me personally that we are yet ready to just accept an incremental half a million cases of COVID-19 and the impact it will have on our society over the next three months, let alone the ability of people to travel, see family for Thanksgiving.
Yep.
All the things we like to do.
Yep.
I personally hope we are aggressive in trying to suppress as much COVID-19 as possible while the pandemic is raging, because I think it's to our collective benefit.
Yep. Thank you.
Thank you. Our next question comes on the line of Joseph Stringer from Needham & Company. Your question, please.
Hi. Thanks for taking our question and thanks for the detailed presentation. My question is sort of related to a previous question, just in terms of sort of the appetite that based on your extensive clinical experience and talking to clinicians and patients and physicians and the like, and Key Opinion Leader in the field, what's sort of the temperature and the appetite, regardless of what the regulatory outcome is for the booster shot for patients getting that booster shot? Thank you.
Thanks, Joseph. It's Paul. Maybe I can just start. Look, one thing we have seen this week is in the United Kingdom, where the Joint Committee on Vaccination and Immunisation recommended with a partnership with Medicines and Healthcare products Regulatory Agency there to the government, which was endorsed to bring out the booster shot, and indeed, the 50 mcg dose of the Moderna vaccine, both in the homologous and heterologous boosting setting. I think that speaks to the sentiment of physicians around the world. We see in other geographies as well that there is a certain fear going into winter. Governments want to protect their healthcare systems, to keep beds open, to keep functioning, and they know that waning immunity will be a barrier to that. It will be a hurdle to do that.
I think there is well-balanced caution about what to do with waning immunity, and that a realization that boosting is a way to protect patients and to protect systems.
Great. Thanks for taking our question.
Thank you. Our final question for today comes from the line of Mani Foroohar from Leerink Partners. Your question, please.
Hi, good afternoon. This is Rick on for Mani. Thanks for taking our questions. I just wanted to touch on the development of the variant-specific boosters. Would the authorization of a 1273 booster change the way the company is currently thinking about the development of the Delta-specific booster? Would you anticipate that the availability of 1273 booster would affect either the pathway to authorization for the variant, in either how the trials are conducted or how regulators would look at the data?
Great. I'll try and take that, Rick, and then invite Jackie to come in if I miss anything. Thanks for the question. First on the variant-specific booster. Our strategy remains that we believe that a multivalent booster is the best way to plan for the future. When it comes to the Delta-specific booster, the good news is we think that the data we have so far on the prototype vaccine mRNA-1273 is that we're going to do well against Delta. That's both real-world evidence data, but also immunogenicity data from the study, including the paper that was published today in "Nature Medicine." We are confident that the prototype vaccine works against Delta. We're advancing a Delta booster candidate in the clinic as we speak to make sure that we have it if it's necessary. We don't think it's going to be necessary.
We do believe that continued expansion of our variant boosters is important, and we think that is mostly about anticipating where the virus goes next. For us, that is a combination booster called mRNA-1273.213, which is a Beta/Delta combination. We think it will cover all of the mutations across Beta, Gamma, and Delta that actually keep us up at night. Not because of the mono-variant version of that, but because we think over time, there's a risk that all of the things that made Delta so good at infecting people could show up in a Beta or Gamma-like strain, which is very good at hiding from our immune system. A combination of transmissibility mutations and immune escape mutations.
The only way we can anticipate what that might look like is we take the things that keep us up at night, that scare us about the current variants, and we combine them in a booster. That's our mRNA-1273.213 program. We do expect that to progress quickly this fall, and we would hope to have that available early next year, if necessary, broadly. Although we hope it's never necessary. If some new, very scary variant emerges, that could be used for that. We are committed to continuing to bring those forward. On the question of regulatory path, in general, the path for these boosters is related to immunogenicity and safety studies, and so bridging immunogenicity studies. The FDA and others have put out guidance of what that needs to look like. Those do not require thousands of people.
It's more like hundreds to demonstrate that you can provide neutralized protection against those variants of concern if they were to emerge. That allows an opportunity for us to develop in smaller numbers at point one, and point two I would offer is that not all countries are going to choose boosting. As Paul just described, the U.K. has already made those recommendations, has moved that direction, including for mRNA-1273. Maybe the U.S. will as well, but those are countries that are on the leading edge of the first round of vaccination, and there are going to still be countries that maybe are going to be looking for boosters and present opportunities for development of novel booster candidates throughout perhaps most of the next year.
We don't think we're foreclosed, and we don't think it's a huge risk if boosters are broadly made available in those countries that are currently six to 12 months from vaccination. Jacqueline, anything you'd add to that?
Yeah, thanks, Stephen. I think you really covered most of it. I guess the one other thing I would say is that, just building on what you said about we're not sure if these boosters would be needed or not. I've felt a lot in the last year that we are fighting a war against this virus and the pandemic. Really the best weapon in that war is clinical information, clinical data. Even if the Delta variant hopefully actually begins to retract as boosters get implemented, we still will have learned from this clinical development program. We will have learned about cross-protection and the reproducibility of being able to generate neutralizing responses against multiple variants. We'll have learned about our ability to combine different sequences in the same vaccine candidate, and that really contributes to the overall strategy for combination respiratory vaccines.
We will have learned more about dosing and administration and longer-term shelf life. I think for all of these reasons, our continued clinical development program is really central to our strategy in the COVID-19 program.
Thank you, Jackie.
Thank you. This does conclude the question and answer session of today's program. I'd like to hand the program back to Stephen Hoge for any further remarks.
Well, thank you all for taking the time to speak to us today and discuss this important data. We continue to believe that our vaccine, mRNA-1273, has been a really important tool in combating the pandemic and the real world evidence supports it. As we talked about today, we think there are reasons to be cautiously concerned about the future through the winter season, and boosting might be necessary for many populations, and that's where we expect or hope we will go in the near future. With that, thank you for the time, thank you for speaking with us, and operator, we'll end the call.
Thank you. Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.